Ginzburg Discusses Most Interesting Presentations From ASH 2021
At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.
Yelena Ginzburg, MD, an associate professor of Medicine, Hematology and Medical Oncology at Mount Sinai, spoke with CancerNetwork® at the 63rd American Society of Hematology Annual Meeting & Exposition, about which abstracts could potentially change the standard of care for patients with polycythemia vera (PV).
Transcript:
There are many agents that are coming through the pipeline. Ultimately, there’s certainly room for rusfertide as a novel agent that may be paradigm shifting, certainly for low-risk, phlebotomy-requiring patients who often suffer from symptomatic iron deficiency that this agent is able to reverse. The symptoms of both PV and systemic iron deficiency appear to be better with this agent based on statistically significant decreases in symptom scores. Rusfertide is certainly novel and poised to change the paradigm, the toolkit, for what options exist for PV patients.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
